A Pilot Study of KPL-914 in Recurrent Pericarditis

Recurrent Pericarditis Clinical Trial

Official title:
An Open-Label Pilot Study of KPL-914 in Recurrent Pericarditis

Status Completed

Clinical Trial Summary

The purpose of this study is to assess the preliminary efficacy and safety of KPL-914 treatment in participants with recurrent pericarditis.

Clinical Trial Description

This is an open-label, single-arm pilot study to explore clinical and biochemical endpoints of pericarditis symptomatology and to collect data to assess inter- and intra-subject variability on both at-baseline and on-treatment parameters. This study consists of 5 distinct Parts, and all participants will be treated with once-weekly subcutaneously (SC)-administered injections of KPL-914.There is an optional 18-week extension period. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03980522
Study type	Interventional
Source	Kiniksa Pharmaceuticals, Ltd.
Contact
Status	Completed
Phase	Phase 2
Start date	January 24, 2018
Completion date	May 17, 2019

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05494788` - Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)	Phase 2
Recruiting	`NCT04687358` - REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
Completed	`NCT03737110` - Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis	Phase 3
Recruiting	`NCT06071156` - Therapy Management in Patients Treated With Anakinra Due to Recurrent Pericarditis	N/A
Not yet recruiting	`NCT05107934` - Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis	Phase 2/Phase 3